Neurocrine Biosciences (Nasdaq: NBIX) has secured US Food and Drug Administration approval for Ingrezza Sprinkle (valbenazine).
The medicine is a new oral granule formulation of Ingrezza, for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.
The advantage of the product is that it provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze